Latest
news

Disclosure of an inside information according to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)

LR HEALTH & BEAUTY SE: PRELIMINARY RESULTS FOR FINANCIAL YEAR 2025 / TARGETED EQUITY CONTRIBUTION / TARGETED RESTRUCTURING OF THE 2024/2028 BONDS

Ahlen, 23 January 2026 – Today, based on the preliminary financial results for the financial year 2025, the Management Board of LR Health & Beauty SE (the “Company”) expects an EBITDA* reported of around EUR 16 million for the financial year 2025 (previously expected to be between EUR 17.0 million and EUR 20.0 million). At the same time, the Management Board of the Company expects sales (revenue from goods sold) of around EUR 277 million for the full year 2025 (previously expected to be between EUR 276 million and EUR 281 million). 

Also today, EY-Parthenon announced the completion of a draft IDW S 6 restructuring opinion in respect of the Company. Pursuant to the analysis set out in that draft restructuring opinion, the Company will for the financial year 2028 achieve an EBITDA* of EUR 27.3 million and sales of EUR 281.5 million in the sensitivity case, and an EBITDA* of EUR 31.4 million as well as sales of EUR 284.7 million in the management case.

Against this background, the Company decided today to enter into discussions with its shareholder and with the bondholders of the Company’s outstanding 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”). The aim of such discussions is to explore the possibility of a financial restructuring of the Company comprising (the following measures together the “Restructuring Measures”):

• an equity contribution from the Company’s shareholder in the amount of EUR 10 million for financing of the Company’s operating business; and 
• bondholder approval of certain amendments to the terms and conditions of the Bonds (through a new written procedure under the Bonds) in respect of:
  • a write-down of 55 % of the nominal amount of the Bonds on a pro rata basis (including the capitalised interest in respect of the interest payments under the Bonds due in November 2025 and February 2026), after which the outstanding nominal amount under the Bonds will amount to EUR 61.3 million;
  • an extension of the term of the Bonds until 31 December 2029;
  • a deferral of the interest payments under the Bonds due in November 2025 and February 2026 (on a capitalising basis and subject to write-down mechanism set out above) and other interest payments under the Bonds due during the period up to and including May 2027 (on a capitalising basis) until the Bonds’ extended maturity date;
  • cash sweep mechanisms for excess cash over a EUR 15 million threshold; and
  • a contractual right (Besserungsschein) for the bondholders to receive cash in an aggregate amount of up to EUR 74.9 million (being equal to the written down amount) out of any excess cash received out of a refinancing of the Bonds.

The holders of the Bonds shall be entitled to participate in the refinancing process.
If the Restructuring Measures cannot be implemented, it is currently assumed that the holders of the Bond could expect an insolvency quota of around 6% in an insolvency liquidation scenario. 

IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de 

*EBITDA, based on IFRS as used in the unaudited consolidated interim report of the Company for Q3 2025 which can be found on the Company’s website at https://media.lrworld.com/IR/Interim_Report_Q3_2025.pdf.

End of inside information

LR Health & Beauty SE: Written Procedure under the 2024/2028 Bonds has been successfully concluded

Ahlen, 28 November 2025 – On 14 November 2025, LR Health & Beauty SE (the “Company”) initiated a written procedure under the terms and conditions for the Company’s 2024/2028 bonds (ISIN: NO0013149658) (the “Bonds”) to request certain temporary waivers relating to postponement of interest payments and non-compliance with the maintenance test (including the leverage covenant) for a period up to and including 28 February 2026 (the “Written Procedure”).

Deadline for voting in the Written Procedure was 15:00 hrs CET today. Votes representing a sufficient part of the adjusted nominal amount of the Bonds were obtained in order to form a quorum and a requisite majority of the adjusted nominal amount voted in favour of the temporary waivers in the Written Procedure.

The agent under the Bonds has further confirmed that the conditions set out in section 4 (Effectiveness) in the notice of the Written Procedure have been fulfilled. Consequently, the temporary waivers are effective immediately.

For further information regarding the Written Procedure, please refer to the notice of the Written Procedure which is accessible on the Company’s website at https://ir.lrworld.com/en/bond/.

LR Group

Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.

Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.

The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.

In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.

LR currently has around 1,200 employees and hundreds of thousands of registered community members.

Contact:

PR Contact: 
LR Health & Beauty SE    
Almut Kellermeyer     
Head of Corporate Communication     
Kruppstraße 55    
59227 Ahlen    
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/

IR Contact: 
cometis AG
Thorben Burbach 
Unter den Eichen 7 | Building D 
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de

Denna kallelse till obligationsinnehavarna är endast utformad på engelska. 

Stockholm, 28 November 2025 

To the Bondholders in: 
ISIN: NO0013149658 – LR Health & Beauty SE EUR 130,000,000 Senior Secured Callable Floating Rate Bonds 2024/2028 

NOTICE OF RESULTS OF WRITTEN PROCEDURE UNDER THE TERMS AND CONDITIONS 

Nordic Trustee & Agency AB (publ) acts as agent (the “Agent”) for the holders of the bonds (the “Bondholders”) in the above mentioned bond issue NO0013149658 with an aggregated amount outstanding of EUR 130,000,000 (the “Bonds”) issued by LR Health & Beauty SE (the “Issuer”). 

All capitalised terms used herein and not otherwise defined in this notice shall have the meanings assigned to them in the terms and conditions of the Bonds as amended and/or restated from time to time (the “Terms and Conditions”). 

Reference is made to the notice of written procedure dated 14 November 2025 (the “Written Procedure” and the “Notice of Written Procedure”) and the request for certain temporary waivers set out therein (the “Temporary Waivers”). 

Votes representing a sufficient part of the Adjusted Nominal Amount of the Bonds have been obtained in order to form a quorum and a requisite majority of the Adjusted Nominal Amount voted in favour of the Temporary Waivers in the Written Procedure. 

The conditions set out in section 4 (Effectiveness) in the Notice of the Written Procedure have been fulfilled. 

In its capacity as Agent, the Agent hereby gives notice to the Bondholders that the Written Procedure has been concluded and that the Temporary Waivers have become effective. 
______________________________________________ 
Stockholm, 28 November 2025 
NORDIC TRUSTEE & AGENCY AB (PUBL) 
as Agent